White M R, Chapman W L, Hanson W L
Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens 30602.
J Parasitol. 1989 Feb;75(1):176-8.
Visceral leishmaniasis is a severe chronic disease of people and animals. The disease is caused by several subspecies of a protozoal organism, Leishmania donovani. If not treated, visceral leishmaniasis is often fatal. The most commonly used chemotherapeutic agents to treat the disease are pentavalent antimonials, which can be toxic, must be administered by parenteral routes, and are sometimes ineffective. In this study, meglumine antimoniate, a pentavalent antimony, was compared with WR 6026, an 8-aminoquinoline derivative, as to antileishmanial efficacy. The results indicate that either of these 2 drugs are effective in the suppression of amastigotes in the liver and spleen of the opossum. Despite the marked parasite suppression in the liver and spleen of the infected opossums, the experimental disease was fatal in all of the infected opossums, regardless of the therapy.
内脏利什曼病是人和动物的一种严重慢性疾病。该疾病由原生动物利什曼原虫杜氏利什曼原虫的几个亚种引起。如果不进行治疗，内脏利什曼病通常会致命。治疗该疾病最常用的化疗药物是五价锑化合物，其可能有毒，必须通过肠胃外途径给药，且有时无效。在本研究中，对五价锑葡甲胺与8-氨基喹啉衍生物WR 6026的抗利什曼原虫疗效进行了比较。结果表明，这两种药物中的任何一种都能有效抑制负鼠肝脏和脾脏中的无鞭毛体。尽管感染负鼠的肝脏和脾脏中的寄生虫受到显著抑制，但无论采用何种治疗方法，实验性疾病在所有感染负鼠中都是致命的。
